Erasca, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+1.47%
vs ±13.2% implied · ×0.11
shaded = implied · ▲▼ = realized
Sentenceour ERAS-12 program, which we acquired from Emerge Life Sciences, Pte. Ltd. (ELS).
ERAS 10-Kaccession 0001193125-26-104150
SentenceERAS-0015, which we license from Guangzhou Joyo Pharmatech Co., Ltd. (Joyo), is also being evaluated in the JYP0015M101 clinical trial in China, which is assessing ERAS-0015 in adult patients with advanced solid tumors harboring specific RAS mutations.
ERAS 10-Kaccession 0001193125-26-104150
SentenceERAS-4001, which we in-licensed from Medshine Discovery Inc. (Medshine)
ERAS 10-Kaccession 0001193125-26-104150
SentenceFollowing this review, in order to prioritize organizational focus and resources to advance our differentiated RAS-targeting franchise, we decided to evaluate strategic alternatives for our naporafenib program, which we in-licensed from Novartis Pharma AG (Novartis).
ERAS 10-Kaccession 0001193125-26-104150
Sentencewe have entered into a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc. (Tango) to enable the evaluation of ERAS-0015 with Tango's PRMT5 inhibitor, vopimetostat, in a Phase 1 clinical trial sponsored by Tango.
ERAS 10-Kaccession 0001193125-26-104150
Erasca has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
Largest filed tie
—
Erasca, Inc.
14.20
Expected move
No implied move.